The cytoplasmic C-terminus of Epstein-Ban' virus (EBV) latent infection membrane protein 1 (LMP1) is essential for B lymphocyte growth transformation and is now shown to interact with a novel human protein (LMP1-associated protein 1 [LAP1]). LAP1 is homologous to a murine protein, tumor necrosis factor receptorassociated factor 2 (TRAF2), implicated in growth signaling from the p80 TNFR. A second novel protein (EBI6), induced by EBV infection, is the human homolog of a second murine TNFR-associated protein (TRAF1). LMP1 expression causes LAP1 and EBI6 to localize to LMP1 clusters in lymphoblast plasma membranes, and LMP1 coimmunoprecipitates with these proteins. LAP1 binds to the p80 TNFR, CD40, and the lymphotoxin-p receptor, while EBI6 associates with the p80 TNFR. The interaction of LMP1 with these TNFR family-associated proteins is further evidence for their role in signaling and links LMPl-mediated transformation to signal transduction from the TNFR family.
Introduction
Epstein-Barr virus (EBV) causes infectious mononucleosis and lymphoproliferative diseases in immune-suppressed patients. EBV is also an important etiologic factor in endemic Burkitt's lymphoma, AIDS-associated central nervous system lymphomas, Hodgkin's disease, and nasopharyngeal carcinoma Miller, 1990) . EBV infection of B lymphocytes is primarily nonlytic, resulting in the expression of EBV-encoded nuclear (EBNAs) and integral membrane proteins (latent infection membrane proteins [LMPs] ) as well as perpetual cell proliferation . EBV recombinantbased molecular genetic analyses have demonstrated that LMP1 and EBNA2, -LP, -3A, and -3C are critical for B lymphocyte transformation (Cohen et al., 1989; Hammerschmidt and Sugden, 1989; Kieff and Liebowitz, 1990; Mannick et al., 1991; Kaye et al., 1993; Tomkinson et al., 1993) , while LMP2, EBNA3B, the EBV-encoded small RNAs and most of the rest of the genome are dispensable Swaminathan et al., 1991; Longnecker et al., 1993; Tomkinson and Kieff, 1992; Robertson et al., 1994) . EBNA1 is also important for transformation since it enhances transcription and replication from EBV episomes (Yates et al., 1984; Reisman and Sugden, 1986) .
LMP1 is not only essential for primary B lymphocyte growth transformation but is also the only EBV gene that has transforming effects in nonlymphoid cells. In Rat1 cells, LMP1 induces growth in lower serum, loss of contact inhibition, anchorage independence, and nude mouse tumorigenicity, while in BALB/c 3T3 cells, LMP1 induces anchorage-independent growth (Wang et al., 1985 (Wang et al., , 1988a Baichwal and Sugden, 1988; Moorthy and ThorleyLawson, 1993) . In B lymphoblasts, LMP1 induces most of the phenotypic effects of EBV infection, including induced expression of activation markers and adhesion molecules, altered growth, and NF-~:B activation (Wang et al., 1988b (Wang et al., , 1990 Hammarskjold and Simurda, 1992; Laherty et al., 1992; Rowe et al., 1994) . In epithelial cells, LMP1 blocks differentiation (Dawson et al., 1990; Fahraeus et al., 1990; Wilson et al., 1990) . These activities are probably relevant to tumorigenicity in humans since LMP1 is expressed not only in EBV-induced lymphoproliferative disease but also in EBV-associated Hodgkin's disease tumor cells and in most anaplastic nasopharyngeal carcinoma cells (Herbst et al., 1991; Pailesen et al., 1991; Brooks et al., 1992; Busson et al., 1992) .
LMP1 is an integral membrane protein that may transform cells by constitutively activating a growth factor receptor pathway common to many cell types (Wang et al., 1985) . LMP1 consists of a 23 amino acid amino-terminal cytoplasmic domain, 6 markedly hydrophobic transmembrane domains separated by short reverse turns, and a 200 amino acid carboxy-terminal cytoplasmic domain (Fennewald et al., 1984; Hennessy et al., 1984) . The transmembrane domains enable LMP1 to posttranslationally insert into membranes and to accumulate in aggregates in the plasma membrane (Hennessy et al., 1984; Liebowitz et al., 1986) .
Recent genetic analyses in primary B lymphocyte growth transformation indicate that the amino terminus is important for tethering of the first transmembrane domain, and the transmembrane domains are important for conferring plasma membrane aggregation (Kaye et al., 1993 (Kaye et al., , 1995 Izumi et al., 1994) . EBV recombinants deleted for the entire 200 or for the last 155 amino acids of the LMP1 carboxy-terminal cytoplasmic domain are incapable of transforming primary B lymphocytes (Kaye et al., 1995) . While the nontransforming phenotype of EBV recombinants deleted for the last 155 amino acids of LMP1 can be transcomplemented by the growth of infected lymphocytes on fibroblast feeders, to date it has not been possible to similarly rescue primary B lymphocytes infected with EBV recombinants deleted for the entire 200 amino acid carboxy-terminal cytoplasmic domain (Kaye et al., 1995) . These results implicate the LM P1 carboxyl terminus in cell growth transformation and suggest that the first 44 amino acids ,may ,be stringently required for transformed cell growth (Kaye et al., 1995) . We have now discovered that the first 44 amino acids of the LMP1 carboxy-terminal cytoplasmic domain interact with a human protein related to the very recently described putative effectors of tumor necrosis factor receptor (TNFR) signaling (Rothe et al., 1994) . The interaction of this human protein with LMP1 and with the cytoplasmic domains of the TNFR family members is evidence for a central role of this protein as an effector of cell growth or death signaling pathways.
Results

A Yeast Two.Hybrid Screen Reveals Proteins That
Interact with the LMP1 Carboxy-Terminal Cytoplasmic Domain DNA encoding the200 amino acid LMP1 carboxy-terminal The yeast strain Y190 was transformed with the indicated plasmids, and transformants were selected on appropriate selective-defined media. Isolated colonies were grown to mid to late log density and assayed for I~-gal activity as described in Experimental Procedures. Four individual transformants were assayed in each case (except for the interaction between G4DBDSNF1 and G4TADSNF4, for which two transformants were tested), and the average values of ~,-Gal units are shown. The interaction between G4DBDSNF1 and G4TADSNF4 was used as a positive control (Harper et al., 1993) and scored 0.8 ~-gal units or higher in different assays.
cytoplasmic domain was fused in frame to the GAL4 DNAbinding domain for use as bait in a yeast two-hybrid screen for cDNAs that encode interactive proteins. The GAL4-activating domain was fused to cDNAs made from RNA from EBV-transformed B lymphocytes (Durfee et al., 1993) . Of 5 x 10 s transformants that were tested for growth in the absence of tryptophane, leucine, and histidine and in the presence of 25 mM 3-aminotriazole, 147 colonies showed at least moderate growth and were analyzed for ~-galactosidase (15-gal) expression. Two clones were strongly positive for 13-gal, scoring higher than 8 U in a standard 13-gal assay, whereas the rest of the clones had nearly background levels of 13-gal activity (less than 0.04 U). The GAL4-activating domain-fusion proteins made from these two clones did not interact with GAL4 DNA-binding domain fusions to p53, pRB, lamin, or the yeast protein kinase SNF1, indicating specificity for the LMP1 cytoplasmic carboxyl terminus. The two clones were 3' coterminal cDNAs from the same mRNA. The clones have a single long open reading frame predicted to encode part of a novel protein provisionally designated LMPl-associated protein 1 (LAP1). To obtain the fulllength LAP1 open reading frame, the insert from the longer clone was used to identify clones from a Xgtl0 library of cDNAs (Birkenbach et ai., 1993) 
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ure 1). The carboxy-terminal LAP1 domain (amino acids 302-568) has 45% colinear amino acid identity to the TNFR-associated factor (TRAF) homology domain of the recently identified murine TRAF1 or -2 (Rothe et al., 1994) . LAP1 is similar to TRAF2 in having an amino-terminal RING finger motif, but is only 27% identical to TRAF2 overall. The longest open reading frame identified in the alternatively spliced LAP1 mRNA encodes for a polypeptide that initiates at methionine codon 350 within the coiled-coil motif of full-length LAP1 and includes the rest of the TRAF domain. Since amino acids 345-568 of LAP1 interact strongly with the LMP1 carboxy-terminal cytoplasmic domain (Table 1 ), the protein encoded by the spliced LAP1 m RNA is likely to interact also with the LM P1 carboxy-terminal cytoplasmic domain and could modulate interactions of LAP1 with LMP1.
A Carboxy-Terminal LAP1 Domain Interacts with a LMP1 Membrane Proximal Cytoplasmic Domain
The interaction of the full-length LMP1 cytoplasmic carboxyl terminus (amino acids 187-386) with the LAP1 carboxy-terminal 386 or 223 amino acid polypeptide scored higher than the positive control in the yeast two-hybrid dependent ~-gal assay (Table 1 ). The interaction of the membrane proximal 44 amino acids of the LMP1 cytoplasmic carboxyl terminus (amino acids 187-231) with the LAP1 carboxy-termina1386 or 223 amino acids also generated higher I~-gal activity than did the positive control (Table 1). Thus, the membrane proximal 44 amino acids of the LMP1 cytoplasmic carboxyl terminus and the LAP1 carboxy-terminal 223 amino acid-TRAF homology domain are sufficient for high level interaction in the yeast two-hybrid assay. The EBV recombinant molecular genetic evidence, which indicates that the LMP1 carbox~-terminal cytoplasmic domain is essential for transformation, provides a linkage between this biochemical interaction and transformation.
An EBV-Induced Cell Protein Is a Human TRAF1 Homolog LAP1 is 32% colinearly homologous to another novel human protein that had been identified because its encoding mRNA is more abundant in the EBV-infected B lymphoblast line BL41/B95-8 than in the uninfected control BL41 cells (Figure 1 ). This EBV-induced mRNA 6 (EBI6) is predicted to encode for a 416 amino acid protein that is 86% colinearly identical to the murine TRAF1 (Rothe et al., 1994) (Figure 1 ). EBI6 is probably the human homolog of murine TRAF1 since these proteins are nearly identical throughout their entire sequence (Figure 1 ). EBI6 and TRAF1 have similar amino-terminal zinc finger motifs and are 95% identical in their TRAF domains (Figure 1 ). When fused to the GAL4-activating domain, EBI6 amino acids 53-416 do not interact in yeast with the LMP1 carboxyterminal cytoplasmic domain or with amino acids 12-568 of LAP1 fused to the GAL4 DNA-binding domain (Table  1 ). The failure of EBI6 to interact with LAP1 distinguishes LAP1 from the murine RING finger protein TRAF2, which 4) and immunoprecipitated material (lanes 5-8) were analyzed by SDS-PAGE on a 7.5 % gel, transferred onto nitrocellulose, and subjected to Western blot analysis using rabbit anti-LM P1 polyclonal antisera (Hennessy et al., 1984 ) and ~2Sl-labeled protein A, followed by autoradiography. The position of LMP1 is shown by the arrow, and molecular weight markers are shown on the right side of the panel. LMP1 was readily coimmunoprecipitated with FLAGLAP1 or FLAGEBI6 (lanes 6 and 7).
No detectable LMP1 was seen in anti-FLAG immunoprecipitations from cells cotransfected with pSG5LMP1 and either vector control (pSG5) or a construct expressing a FLAG-tagged EBNA2 (FLAGE2, lanes 5 and 8).
scored positive in the yeast two-hybrid system with TRAF1 (Rothe et al., 1994) . While the failure could be due to differences between the human RING finger (LAP1) or zinc finger (EBI6) TRAFs and murine TRAF1 and -2, the lower level of homology of LAP1 to TRAF2 is more likely to account for this discrepancy given the extensive identity between EBI6 and LAP1.
Expression of LAP1 and EBI6 in Human Tissues and Cell Lines
The full-length 2.8 kb and alternatively spliced 1.8 kb LAP1 mRNAs are expressed in all tissues examined ( Figure 2A ). In contrast, the 2.6 kb EBI6 mRNA is readily detected in lung, spleen, and tonsil, is barely detected in placenta, and is not detectable in pancreas, kidney, smooth muscle, liver, brain, or heart ( Figure 2B ; data not shown). To evaluate the effects of EBV infection on LAP1 and EBI6 mRNA abundance, LAP1 or EBI6 probes were hybridized to RNAs from EBV-negative BL41 B lymphoblasts, from EBV-infected BL41 B lymphoblasts (BL41/B95-8), or from an EBV-transformed B lymphoblast cell line (IB4) ( Figures 2C and 2D ). LAP1 mRNAs were similarly abundant in EBV-positive or -negative cells, whereas the EBI6 message was at least 8-fold more abundant in the EBV-infected BL41/B95-8 or IB4 cells than in noninfected BL41 cells.
LMP1 Associates with LAP1 and EBI6
in B Lymphoblasts LMP1 and FLAG epitope-tagged LAP1 (FLAGLAP1) or FLAG-tagged EBI6 (FLAGEBI6) were expressed in an efficiently transfectable non-EBV-infected human B lymphoblast cell line (BJAB). As controls, LMP1 and FLAG epitope-tagged EBNA2 (FLAGEBNA2) were expressed in B JAB cells. Approximately 18 hr posttransfection, the cells were lysed in nonionic detergent; FLAG fusion proteins were immunoprecipitated with an anti-FLAG monoclonal antibody; and LMP1 was detected by Western blotting (Hennessy et al., 1984) . LMP1 was expressed at similar levels in all transfections (Figure 3, lanes 1-4) . A substantial fraction of LMP1 immunoprecipitated along with FLAG-LAP1 or FLAGEBI6 and did not immunoprecipitate along with FLAGEBNA2 ( Figure 3, lanes 4-8) . Thus, LMP1 specifically associates with LAP1 or EBI6 in B lymphoblasts. Figures 4K and 4N , respectively). FLAGEBI6 did not localize as precisely with LMP1 as did FLAGLAP1, suggesting a weaker, less direct, or more transient interaction with LMP1. Thus, LMP1 expression redirects LAP1 and (to a lesser extent) EBI6 from scattered cytoplasmic structures to LMP1 plasma membrane patches.
LMP1 Redirects the
LAP1 and EBI6 Associate with TNFR Family Cytoplasmic-Domains
The homology of LAP1 and EBI6 to routine TRAF2 and TRAF1 prompted us to examine whether LAP1 and EBI6 can interact with members of the TNFR family, including CD40, lymphotoxin-I~ receptor (LTI~R), and Fas Nagata, 1994; Smith et al., 1994; Ware et al., 1995) , using receptor cytoplasmic domains constructed as fusion proteins with glutathione S-transferase (GST). In vitro translated LMP1 did not interact with GST or GST fusions to TNFRs ( Figure 5A, lanes 1-3) . However, in vitro translated LAP1 bound specifically (112-fold over GST background) to the p80 cytoplasmic domain and less well (14-fold over GST background) to the p60 cytoplasmic domain ( Figure 5A , lanes 4-6; Figure 5B , lanes 3 and 4; data not shown). LAP1 also showed nearly quantitative binding to the cytoplasmic domains of TNFR-related proteins CD40 and LTI~R and less efficient binding to Fas ( Figure 5B ). EBI6 bound less efficiently than did LAP1 to p80 and showed weak binding to p60 ( Figure 5A , lanes 7-9). LAP1 and EBI6 also associate with the p80 receptor in vivo. The p80 TNFR was coexpressed with FLAGLAP1, FLAGEBI6, or FLAGEBNA2 in B JAB cells that do not express any surface pS0 receptor (data not shown). FLAGtagged proteins were immunoprecipitated from cell lysates using M2 anti-FLAG antibody, and the immune complexes were analyzed for the presence of p80 TNFR by Western blotting ( Figure 5C ). The M2 anti-FLAG antibody coimmunoprecipitated the p80 receptor from cells The intracellular distribution of FLAG-tagged LAP1 and EBI6 was determined by indirect immunofluorescence using M2 anti-FLAG monoclonal antibody and rabbit anti-LMP1 polyclonal antisera. B JAB cells were transfected with FLAGLAP1 (A, B, and E-J) or FLAGEBI6 (C, D, and K-P) expressing constructs in the presence of vector pSG5 (A-D) or pSG5LMP1 (E-P). M2 anti-FLAG reactivity was visualized with a fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody (A, C, E, H, K, N). LMP1 was detected with a Texas Redconjugated goat anti-rabbit secondary antibody (F, I, L, O). Phasecontrast pictures are shown in (B), (D), (G), (J), (M), and (P). M2 and anti-LMP1 antibodies did not show any reactivity in untransfected cells. No cross-reactivity was observed between M2 and the goat anti-rabbit secondary antibody or between the rabbit anti-LMP1 and goat antimouse secondary antibody (data not shown). e x p r e s s i n g FLAGLAP1 or F L A G E S I 6 ( Figure 5C , lanes 1 and 2), but not from cells e x p r e s s i n g F L A G E B N A 2 ( Figure  5C , lane 3). FLAGLAP1 and F L A G E B I 6 a s s o c i a t e d with both the -7 0 k D a precursor and the m a t u r e p80 T N F R (Ware et al., 1991) , indicating that the association with LAP-1 occurs prior to receptor e x p r e s s i o n at the cell surface. T h e s e studies indicate the potential of LAP1 and EBI6 to participate in T N F R signaling and also provide e v i d e n c e that LAP1 m a y be a c o m p o n e n t c o m m o n to the CD40, LTI3R, and T N F R signal transduction pathways. 
Discussion
We have identified two human TRAFs and confirmed their association with the human p80 TNFR. The TRAF domain was initially defined because of more than 50% colinear primary sequence identity through the carboxy-terminal 230 amino acids of murine TRAF1 and -2 (Rothe et al., 1994) . Genetic and biochemical data link TRAF1 and -2 to the growth and NF-•B-transducing effects of a domain near the carboxyt terminus of the p80 TNFR cytoplasmic tail (Rothe et al., 1994) . EBI6 is almost certainly the human TRAF1, based on the ability of both proteins to associate with the p80 TNFR, similar tissue restricted expression, similar amino-terminal zinc finger motifs, 95% primary sequence identity in the TRAF domains, and an overall 86% colinear primary sequence identity. LAP1 is probably not the human TRAF2, but rather a human RING finger analog. If so, there may be one or more human RING finger TRAFs as yet unidentified. Although LAP1 and TRAF2 are similar in size, have an amino-terminal RING finger domain, and are constitutively expressed in most tissues, LAP1 is 45% identical to either TRAF2 or TRAF1 in the TRAF domain and is quite divergent from TRAF2 outside of the TRAF domain. Overall, LAP1 and TRAF2 are only 27% identical. LAP1 also appears to be functionally distinct from TRAF2 in not directly interacting with EBI6, the human TRAFI. LAP1 and EBI6 interact with the cytoplasmic domain of not only p80 TNFR but also with p60 TNFR, albeit less well than with p80. This is the first evidence of interaction beyond p80 between these putative effectors and the TNFR family. Indeed, LAP1 also interacts strongly with the LTI3R and CD40 cytoplasmic domains. These findings provide a new molecular basis for understanding the common effects of activation of these members of the TNFR family. Heterogeneity among TRAFs or other cell proteins may provide components to the receptor-TRAF complexes that determine the specific phenotypic outcome(s) of receptor activation.
The identification of these human TRAFs is in the context of an investigation into the mechanisms by which LMP1 transforms cells. These biochemical and genetic experiments and previous EBV recombinantmolecular genetic analysis establish a connection between the role of LMP1 in B lymphocyte growth transformation and TNFR signaling pathways. As briefly reviewed in the introduction, LMP1 is a dominant oncogene that has multiple downstream effects on cell growth and gene expression, at least some of which are NF-KB mediated. LMP1 interacts strongly and directly with LAP1 and also associates with EBI6 in human lymphoblasts. Our genetic, biochemical, and intracellular localization data on the association of ~LMP1 with LAP1 and EBI6, taken together with the previous genetic and biochemical linkage of TRAF1 and -2 to p80 TNFR signaling, reinforce a role for the TRAFs as mediators of cell growth or death and NF-~B responses (for schematic model, see Figure 6 ). , The six markedly hydrophobic transmembrane domains of LMP1 enable it to aggregate in the plasma membrane and to present aggregated cytoplasmic domains to the (B) Three LMP1 molecules are shown to form a constitutive complex at the plasma membrane (depicted by the stippled area between the two solid horizontal lines). The amino-terminal (N) and carboxyterminal (C) cytoplasmic regions of LMP1 are shown by short and long lines, respectively. The transmembrane domains of LMP1 are depicted by vertical cylinders, which are joined by short reverse turns (short curved lines). Aggregation of LMP1 molecules at the plasma membrane brings together LMPl-associated TRAF molecules ('rRAF) in a complex, thus, generating a constitutive signal that results in pleiotropic effects, including activation of NF-KB (NFkB) and cell growth.
TRAFs ( Figure 6B ). In presenting aggregated TRAFinteracting domains, LMP1 mimics TNFR aggregation, which appears to be essential for signal transduction (Engelmann et al., 1990; Loetscher et al., 1991; Pennica et al., 1992; Tartaglia and Goeddel, 1992) . Receptor crosslinking probably locally aggregates TRAFs and associated molecules, creating a second messenger signal perhaps mediated by a receptor-associated serine/threonine kinase ( Figure 6A ) (Darnay et al., 1994a (Darnay et al., , 1994b VanArsdale and Ware, 1994) . Since LMP1 constitutively aggregates LAP1 and EBI6 in oligomeric complexes at plasma membrane patches, these complexes could constitutively activate growth signals and NF-KB in the absence of extracellular stimuli ( Figure 6B ). LM P1 signaling via TRAF molecules may thus proceed independently of TNFR molecules. Alternatively, LMP1-TRAF aggregates may nucleate larger, more diverse, or more stable TNFR family-TRAF complexes through interactions among the extended coiled-coils of the TRAF domains. In fact, some evidence favors the latter alternative in that lymphotoxin-~ (LT(~) is an autocrine growth factor for EBV-transformed lymphoblastoid cell lines (Estrov et al., 1993; Gibbons et al., 1994) . Furthermore, expression of the full range of EBV latent infection-associated proteins in Burkitt lymphoma cell lines induces LTa and the p80 receptor (Gibbons et al., 1994) . Moreover, antagonistic antibodies to the p60 TNFR have a negative growth effect in such cells (Gibbons et al., 1994) . The LMP1 cytoplasmic carboxy-terminal domain and TNFR family members could even interact with different domains of the same LAP1 molecule since there is no obvious homology between the LMP1 cytoplasmic carboxyl terminus and the cytoplasmic domains of TNFR family members. The induction of EBI6 by latent EBV infection and the association of EBI6 with I_MP1 in B lymphoblasts are also evidence of an important role for EBI6 in EBV-mediated B lymphocyte growth transformation. The interaction appears to be less direct than with LAP1 and may be mediated by another as yet unidentified human RING finger TRAF.
TNF and CD40 ligand are well known mediators of growth of B lymphocytes and of other cell types that are targets for LMPl-transforming effects (Noelle et al., 1992; Boussiotis et al., 1994) . In fact, CD40 ligation and interleukin-4 treatment are sufficient to sustain the proliferation of primary B lymphocytes in vitro for several months, and the cells are phenotypically similar to EBV-transformed lymphocytes (Saeland et al., 1993; Banchereau et al., 1994; Galibert et al., 1994) . The LTI3R is expressed on epithelial cells (C. W. and J. Browning, unpublished data), while basal epithelial cells and anaplastic nasopharyngeal carcinoma cells also express high levels of CD40 (Busson et al., 1988; Young et al., 1989) . LMP1, through constitutive direct interaction with LAP1, may amplify or usurp LTI~R and CD40 signal transduction and constitutively promote cell growth. Nasopharyngeal carcinoma is tightly associated with EBV, and LMP1 is frequently expressed in the tumor cells (Brooks et al., 1992 ). Hodgkin's disease is another EBV-associated malignancy in which LMP1 is expressed (Herbst et al., 1991) . CD40, TNFRs, and the related receptor CD30 are up-regulated in Hodgkin's disease cells (Froese et al., 1987; Pfreundschuh et al., 1989; Carde et al., 1990; O'Grady et al., 1994; Trumper et al., 1994) . A potentially important consequence of the demonstrated interaction between LAP1 and LMP1 is that inhibitors of that interaction may affect the growth or development of these LMPl-associated malignancies.
In interacting with components of receptor signaling, LMP1 is reminiscent of bovine papilloma virus E5. Bovine papilloma virus E5 dimerizes in the plasma membrane, presumably through hydrophobic interactions, and activates receptors for epidermal growth factor, platelet-derived growth factor, or colony-stimulating factor 1 (Martin et al., 1989; Petti et al., 1991; Petti and DiMaio, 1992) . E5 binds a component of vacuolar H+-ATPases, and this may affect receptor recycling (Goldstein et al., 1991) .
A curious aspect of our data is the finding that LAP1 or EBI6 localized to vesicle-like structures in the cytoplasm of B lymphoblasts. Furthermore, LAP1 is constitutively expressed in cells, and there may be another constitutively expressed RING finger protein that intermediates between LMP1 and EBI6. These Constitutively expressed proteins may also have a role in vesicle biology.
The interaction of LMP1 with TNFR signaling pathways may also be important in enabling EBV-infected cells to evade cellular host defense mechanisms in latent or lytic EBV infection. LMP1 is one of the few EBV genes expressed in both phases of the virus life cycle (Mann et al., 1985; Rowe et al., 1992) . Several virus families appear to specifically target the TNF/lymphotoxin pathways, presumably to avoid these immune cell mediators of cytotoxicity. Pox viruses produce soluble versions of the p80 TNFR Massung et al., 1993) ; proteins encoded by the adenovirus E3 region block the apoptotic function of TNF (Gooding, 1992) ; and HIV utilizes NF-KBactivating signals induced by TNF signaling to enhance transcription (Poli et al., 1990) . The binding of EBV LMP1 to LAP1 may effectively compete with normal LAP1 binding to the p60 TNFR, blocking the induction of cell death mediated by that receptor (Tartaglia et al., 1993b) or blocking other functions critical to host defense (Pfeffer et al., 1993; Rothe et al., 1993) , while simultaneously usurping the growth-promoting signals of the ~)80 TNFR (Tartaglia et al., 1993a) .
Experimental Procedures Plasmid Construction
The GAL4 DNA-binding domain (G4DBD) fusions were constructed in vector pAS2 (Harper et al., 1993) . G4DBDLMPI(187-386) was constructed by polymerase chain reaction-mediated (PCR-mediated) amplification of the LMP1 cDNA fragment, encoding amino acids 187-386, using oligos L1-5PCR (5'-CGCGGATCCATGGACAACGACA-CAGTG-3') and L1-4PCR (5'-CGCGGATCCTTAGTCATAGTAGCT-TAG-39, followed by cloning into the BamHI site of pAS2. G4D-BDLMP1(187-231) was constructed by PCR amplification of the LMP1 cDNA fragment, encoding amino acids 187-231, using oligos L1-5PCR and LCA231 (5"CGCGGATCCTTAGGCTCCACTCACGAG-CAG-3~, followed by cloning into the BamHI site of pAS2. G4DBDL-AP1(12-568) was constructed by isolating the BssHII-BamHI fragment of LAP1 cDNA from pSG5LAP1, blunt-ending it using T4 DNA polymerase, and subcloning it into the Smal site of pASI. GAL4 transactivating domain (G4TAD) fusions were as follows. G4TA-DEBI6(53-416) was constructed by subcloning the Bglll fragment of EBI6 cDNA into the BamHI site of pACTII (a gift of S. EUedge). G4TA-DEBI6(53-416) encodes for an in-frame fusion of EBI6 amino acids 53-416 to the acidic transactivating domain of GAL4. Plasmids G4TADLAP1 (183-568) and G4TAD LAP1(345-568) were isolated from the yeast two-hybrid screening. Plasmids expressing SNF1 fused to the DNA-binding domain of GAL4 (G4DBDSNF1) or SNF4 fused to the activation domain of GAL4 (G4TADSNF4) were gifts of S. Elledge. SNF1 and SNF4 are two yeast proteins that are known to interact with each other, and they were used as a positive control in the yeast two-hybrid-dependent l}-gal assay (Harper et al., 1993) . LAP1 cDNAs were subcloned into the EcoRI site of plasmid pSG5 (Stratagene) for sequencing analysis, pSG5 subclones of the longest LAP1 cDNAs were spliced at the Nrul site to generate the full-length LAP1-expressing construct pSG5LAP1. The EcoRI insert of Zgtl0 clone EBI6 was subcloned into the plasmid pBluescript for sequencing analysis. pSG5FLAGLAP1 and pSG5FLAGEBI6 were constructed in vector pSG5 by placing through PCR a FLAG-encoding DNA fragment just after the initiator AUG codon. Expression plasmids for TNFRs were previously described (Ware et al., 1991) .
Subtractive Hybridization
Construction of the ~.gtl 0 cDNA library from the EBV-positive cell line BL41/B95-8 was previously described (Birkenbach et al., 1993) . Subtractive hybridization and homology screening of the Xgtl0 library was done as described before (Birkenbach et al., 1993) .
Yeast Two-Hybrid Screening
Yeast transformation was performed according to the method of Schiestl and Geitz (1989) . The yeast strain Y190 (Du rfee et al., 1993) was transformed with plasmid construct G4DBDLMP 1(187-386), and transformants were plated on Trp selective-defined media. A single colony was picked, and the expression of the LMP1 fusion protein was verified by Western blotting using the $12 anti-LMP1 monoclonal antibody. The G4DBDLM P 1 (187-386) transformant was subsequently transformed with a cDNA library constructed previously from an EBVtransformed lymphoblastoid cell line (Durfee et al., 1993) , and selection was done on Trp Leu-His-selective-defined media in the presence of 25 mM 3-aminotriazole (Sigma) as previously described (Durfee et al., 1993) . Colonies that showed moderate to intense growth were streaked on Trp-Leu-Hi~ selective-defined media containing 50 mM 3-aminotriazole and tested for 13-gal expression by a filter lift assay (Breeden and Nasmyth, 1985) . For quantitation of ~-gal expression, yeast clones were grown in appropriate selective media to ODsoo of 0.5-1.2 and were assayed for ~-gal activity using ONPG and standard conditions as previously described (Breeden and Nasmyth, 1985) . I~-Gal units were expressed as (1000/hls)/(assay time in minutes)(ceU culture volume in milliliters)(OD~). The interactions of G4DBD with G4TADLAPl(183-568), G4TADLAPl(346-568), or G4TADEBI6(53-416) and of G4TAD with G4DBDLMP1(187-386), G4DBDLMPl(187-231), or G4DBDLAP1(12-568) scored ~<0.1 U of ~-gal. Library-derived piasmids were recovered by transformation of competent bacteria with total yeast DNA preps, followed by selection for ampicillin resistance as previously described (Ausubel et al., 1987) .
Northern Blots
Northern blots containing poly(A) ÷ RNA (2 p.g per lane) from eight human tissues were purchased from CLONTECH. RNA was prepared from EBV-positive (BL41/B95-8) or EBV-negative (BL41) Burkitt's lymphoma cell lines and a lymphoblastoid cell line (IB4) as previously described (Birkenbach et al., 1993) . cDNA probes were labeled by random hexanucleotide priming (Stratagene) using [32P]dCTP. The RNA blots were hybridized to 32P-labeled cDNA probes under high stringency conditions as described (Mosialos et al., 1994) . Northern blot filters were exposed to autoradiography film or were processed by phosphorimager analysis.
Immunoprecipitations, Western Blotting, and Immunofluorescence BJAB cells were eiectroporated at 220 V and 960 p~F in 400 pl of RPMI-1640 medium containing 10% fetal calf serum. Approximately 20 hr posttranfection, cells were lysed for 30 rain on ice in 0.5% NP-40 lysis buffer containing 50 mM HEPES (pH 7.4), 250 mM NaCI, 10% glycerol, 2 mM EDTA, 1 mM PMSF, 2 i~g/ml aprotinin, 2 i~g/ml pepstatin A, and 2 ~g/ml leupeptin. Cell debris were removed by centrifugation at 10,000 x g for 10 rain at 4°C. The cell lysates were precieared with protein G-Sepharose beads for I hr at 4°C. The primary antibody was then added for 1 hr at 4°C, and immunoglobulin complexes were collected on protein G-Sepharose beads for 1 hr at 4°C. The beads were then washed six times with 1 ml of lysis buffer each time, and protein complexes were recovered by boiling in SDS sample buffer and were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting was done using standard techniques as previously described (Mosiales et al., 1994) .
Indirect immunofluorescence analysis on transfected cells was done approximately 18-20 hr posttransfection as previously described (Mosialos et al., 1994) .
Production and Purification of GeT-Fusion Proteins
The cytoplasmic domains Of the p80 and p60 TNFRs were amplified from the corresponding cDNAs by PCR and were cloned in frame into the pGEX-4T-1 expression vector (Pharmacia) using the EcoRI and Xhol restriction sites for the p60 TNFR and the EcoRI and Xhol sites for the p80 TNFR. A similar strategy was employed for the construction of a GST fusion to the LT~R cytoplasmic domain. GST-fusion proteins of the cytoplasmic domains of CD40 and Fas were a gift of J. Reed (La Jolla Cancer Research Institute). Expression and purification of GST-fusion proteins were performed essentially as described previously (Smith and Johnson, 1988) . Fusion protein concentrations of 3-5 mg/ml of glutathione-agarose beads (Pharmacia) were routinely obtained. In vitro translations were done using the rabbit reticulocytecoupled in vitro transcription translation system (TNT, Promega) according to the protocol of the manufacturer. In vitro translated proteins were diluted with binding buffer (PBS containing 0.1% NP-40, 0.5 mM DTT, 10% glycerol, 1 mM PMSF, 2 i~g/mi aprotinin) and were preclearad with glutathione beads for 45 rain at 4°C. GST or GSTfusion proteins bound to glutathiene beads were then incubated with in vitro translated proteins for 1 hr at 4°C. The beads were subsequently washed five times with 0.5 ml of binding buffer each time, and bound proteins were recovered by boiling in SDS sample buffer and were analyzed by SDS-PAGE.
